BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1410 related articles for article (PubMed ID: 28102896)

  • 21. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.
    Hoffmeister PA; Storer BE; Macris PC; Carpenter PA; Baker KS
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1081-6. PubMed ID: 23623893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
    Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM; Devine SM; Andritsos LA
    Bone Marrow Transplant; 2014 Oct; 49(10):1323-9. PubMed ID: 25068419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation.
    Maris MB; Storb R
    Acta Haematol; 2005; 114(4):221-9. PubMed ID: 16269862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
    Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
    Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
    Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
    Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
    Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.
    Hiramoto N; Kurosawa S; Tajima K; Okinaka K; Tada K; Kobayashi Y; Shinohara A; Inoue Y; Ueda R; Tanaka T; Kim SW; Yamashita T; Heike Y; Fukuda T
    Eur J Haematol; 2014 Feb; 92(2):137-46. PubMed ID: 24127668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission.
    Holter Chakrabarty JL; Rubinger M; Le-Rademacher J; Wang HL; Grigg A; Selby GB; Szer J; Rowe JM; Weisdorf DJ; Tallman MS
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1021-5. PubMed ID: 24691221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
    Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y
    Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
    Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
    Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
    Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
    Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.